{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:10:45Z","timestamp":1781629845122,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Helmholtz Zentrum M\u00fcnchen - Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt (GmbH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetes complications manifest across various organs, but are fundamentally rooted in vascular dysfunction. This study aims to identify plasma protein signatures that improve prediction of macrovascular and microvascular complications in type 2 diabetes over classical clinical factors, assess the stability of their prognostic performance over time, and explore the cross-ancestry generalizability of the developed models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 2,923 plasma proteins in 917 European-ancestry UK Biobank participants with prevalent type 2 diabetes but no prior vascular disease at baseline. The primary outcomes were time to first macrovascular or microvascular complication, identified through ICD-10 codes during a mean follow-up of 10.41 years. Protein selection was performed using clinical-variables-prioritized LASSO Cox regression across 100 resamples to identify proteins offering predictive value beyond established clinical markers. Stably selected proteins were then integrated with and evaluated against clinical-only models using optimism-corrected C-index, time-dependent AUC and Brier score. We also conducted exploratory analyses to assess model generalizability in 116 European genetic outliers and in 80 Asian and 54 African ancestry participants within the UK Biobank.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For macrovascular outcomes, 37 proteins were selected, led by LRRC37A2, NT-proBNP, CHGA, APOD and STAB2. For microvascular complications, 9 proteins were selected, led by IL15, FAM3C and TNFSF11, with overall more moderate stability across resampling. The proteomics-integrated models significantly improved prediction of type 2 diabetes vascular complications beyond clinical markers (Harrell\u2019s C: macrovascular 0.72 vs. 0.60; microvascular 0.67 vs. 0.62) and demonstrated stable prognostic accuracy over 10 years for macrovascular outcomes. In exploratory generalizability analyses, predictive gains of proteomics integration were maintained in European genetic outliers but diminished in African and Asian participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Integrating proteomics with clinical data enhances risk prediction of type 2 diabetes vascular complications, especially for macrovascular outcomes. However, less precise prediction for microvascular complications and preliminary evidence of limited cross-ancestry generalizability highlight the need to expand targeted biomarker panels and quantification in larger, more ancestry-diverse cohorts to ensure effective and equitable clinical implementation of proteomics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-026-03083-6","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:06:30Z","timestamp":1768896390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integration of clinical and proteomic risk factors enhances prognostic modelling of incident vascular complications in type 2 diabetes"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-7017","authenticated-orcid":false,"given":"Yue","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Tutino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel William","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Barysenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2467-9236","authenticated-orcid":false,"given":"Ozvan","family":"Bocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4238-659X","authenticated-orcid":false,"given":"Eleftheria","family":"Zeggini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"3083_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-018-0703-2","volume":"17","author":"WD Strain","year":"2018","unstructured":"Strain WD, Pald\u00e1nius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;17:57. https:\/\/doi.org\/10.1186\/s12933-018-0703-2.","journal-title":"Cardiovasc Diabetol"},{"key":"3083_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40139-020-00205-x","volume":"8","author":"RI Mota","year":"2020","unstructured":"Mota RI, Morgan SE, Bahnson EM. Diabetic vasculopathy: macro and microvascular injury. Curr Pathobiol Rep. 2020;8:1\u201314. https:\/\/doi.org\/10.1007\/s40139-020-00205-x.","journal-title":"Curr Pathobiol Rep"},{"key":"3083_CR3","doi-asserted-by":"publisher","first-page":"e14656","DOI":"10.1111\/dme.14656","volume":"38","author":"J Leal","year":"2021","unstructured":"Leal J, Alva M, Gregory V, Hayes A, Mihaylova B, Gray AM, et al. Estimating risk factor progression equations for the UKPDS outcomes model 2 (UKPDS 90). Diabet Med. 2021;38:e14656. https:\/\/doi.org\/10.1111\/dme.14656.","journal-title":"Diabet Med"},{"key":"3083_CR4","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.2337\/dc19-0587","volume":"42","author":"MW Segar","year":"2019","unstructured":"Segar MW, Vaduganathan M, Patel KV, McGuire DK, Butler J, Fonarow GC, et al. Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score. Diabetes Care. 2019;42:2298\u2013306. https:\/\/doi.org\/10.2337\/dc19-0587.","journal-title":"Diabetes Care"},{"key":"3083_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S2213-8587(17)30221-8","volume":"5","author":"S Basu","year":"2017","unstructured":"Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of risk equations for complications of type 2 diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol Elsevier. 2017;5:788\u201398. https:\/\/doi.org\/10.1016\/S2213-8587(17)30221-8.","journal-title":"Lancet Diabetes Endocrinol Elsevier"},{"key":"3083_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01400-z","volume":"8","author":"Y Li","year":"2023","unstructured":"Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther Nat Publishing Group. 2023;8:1\u201329. https:\/\/doi.org\/10.1038\/s41392-023-01400-z.","journal-title":"Signal Transduct Target Ther Nat Publishing Group"},{"key":"3083_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol Nat Publishing Group. 2022;18:525\u201339. https:\/\/doi.org\/10.1038\/s41574-022-00690-7.","journal-title":"Nat Rev Endocrinol Nat Publishing Group"},{"key":"3083_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction\u2013Associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early Intervention. A consensus report of the American diabetes association. Diabetes Care. 2025;48:1057\u201382. https:\/\/doi.org\/10.2337\/dci24-0094.","journal-title":"Diabetes Care"},{"key":"3083_CR9","doi-asserted-by":"publisher","first-page":"103209","DOI":"10.1016\/j.dsx.2025.103209","volume":"19","author":"A Misra","year":"2025","unstructured":"Misra A, Kumar A, Kuchay MS, Ghosh A, Gulati S, Choudhary NS, et al. Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes. Diabetes Metab Syndr Clin Res Rev. 2025;19:103209. https:\/\/doi.org\/10.1016\/j.dsx.2025.103209.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"3083_CR10","doi-asserted-by":"publisher","unstructured":"Carrasco-Zanini J, Pietzner M, Davitte J, Surendran P, Croteau-Chonka DC, Robins C, et al. Proteomic signatures improve risk prediction for common and rare diseases. Nat Med Nat Publishing Group. 2024;1\u201310. https:\/\/doi.org\/10.1038\/s41591-024-03142-z.","DOI":"10.1038\/s41591-024-03142-z"},{"key":"3083_CR11","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s44161-024-00567-0","volume":"3","author":"A Schuermans","year":"2024","unstructured":"Schuermans A, Pournamdari AB, Lee J, Bhukar R, Ganesh S, Darosa N, et al. Integrative proteomic analyses across common cardiac diseases yield mechanistic insights and enhanced prediction. Nat Cardiovasc Res Nat Publishing Group. 2024;3:1516\u201330. https:\/\/doi.org\/10.1038\/s44161-024-00567-0.","journal-title":"Nat Cardiovasc Res Nat Publishing Group"},{"key":"3083_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s43587-024-00655-7","volume":"4","author":"DA Gadd","year":"2024","unstructured":"Gadd DA, Hillary RF, Kuncheva Z, Mangelis T, Cheng Y, Dissanayake M, et al. Blood protein assessment of leading incident diseases and mortality in the UK biobank. Nat Aging Nat Publishing Group. 2024;4:939\u201348. https:\/\/doi.org\/10.1038\/s43587-024-00655-7.","journal-title":"Nat Aging Nat Publishing Group"},{"key":"3083_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cell.2024.10.045","volume":"188","author":"Y-T Deng","year":"2025","unstructured":"Deng Y-T, You J, He Y, Zhang Y, Li H-Y, Wu X-R, et al. Atlas of the plasma proteome in health and disease in 53,026 adults. Cell. 2025;188:253\u2013e2717. https:\/\/doi.org\/10.1016\/j.cell.2024.10.045.","journal-title":"Cell"},{"key":"3083_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12933-024-02143-z","volume":"23","author":"H Luo","year":"2024","unstructured":"Luo H, Huemer M-T, Petrera A, Hauck SM, Rathmann W, Herder C, et al. Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study. Cardiovasc Diabetol. 2024;23:53. https:\/\/doi.org\/10.1186\/s12933-024-02143-z.","journal-title":"Cardiovasc Diabetol"},{"key":"3083_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2337\/dc24-1696","volume":"48","author":"H Yu","year":"2025","unstructured":"Yu H, Zhang J, Qian F, Yao P, Xu K, Wu P, et al. Large-Scale plasma proteomics improves prediction of peripheral artery disease in individuals with type 2 diabetes: A prospective cohort study. Diabetes Care. 2025;48:381\u20139. https:\/\/doi.org\/10.2337\/dc24-1696.","journal-title":"Diabetes Care"},{"key":"3083_CR16","doi-asserted-by":"publisher","unstructured":"Ye Z, Zhang Y, Zhang Y, Yang S, He P, Liu M, et al. Large-Scale proteomics improve prediction of chronic kidney disease in people with diabetes. Diabetes Care. 2024;dc240290. https:\/\/doi.org\/10.2337\/dc24-0290.","DOI":"10.2337\/dc24-0290"},{"key":"3083_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-024-00671-z","volume":"4","author":"M Smelik","year":"2024","unstructured":"Smelik M, Zhao Y, Mansour Aly D, Mahmud AF, Sysoev O, Li X, et al. Multiomics biomarkers were not superior to clinical variables for pan-cancer screening. Commun Med Nat Publishing Group. 2024;4:1\u20138. https:\/\/doi.org\/10.1038\/s43856-024-00671-z.","journal-title":"Commun Med Nat Publishing Group"},{"key":"3083_CR18","doi-asserted-by":"publisher","first-page":"bbaa167","DOI":"10.1093\/bib\/bbaa167","volume":"22","author":"M Herrmann","year":"2021","unstructured":"Herrmann M, Probst P, Hornung R, Jurinovic V, Boulesteix A-L. Large-scale benchmark study of survival prediction methods using multi-omics data. Brief Bioinform. 2021;22:bbaa167. https:\/\/doi.org\/10.1093\/bib\/bbaa167.","journal-title":"Brief Bioinform"},{"key":"3083_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-019-0802-0","volume":"19","author":"A Volkmann","year":"2019","unstructured":"Volkmann A, De Bin R, Sauerbrei W, Boulesteix A-L. A plea for taking all available clinical information into account when assessing the predictive value of omics data. BMC Med Res Methodol. 2019;19:162. https:\/\/doi.org\/10.1186\/s12874-019-0802-0.","journal-title":"BMC Med Res Methodol"},{"key":"3083_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and the European association for the study of diabetes (EASD). Eur Heart J. 2020;41:255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"key":"3083_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK biobank. Nat Nat Publishing Group. 2023;622:329\u201338. https:\/\/doi.org\/10.1038\/s41586-023-06592-6.","journal-title":"Nat Nat Publishing Group"},{"key":"3083_CR22","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779. https:\/\/doi.org\/10.1371\/journal.pmed.1001779.","journal-title":"PLoS Med"},{"key":"3083_CR23","doi-asserted-by":"publisher","first-page":"e1011346","DOI":"10.1371\/journal.pgen.1011346","volume":"20","author":"O Bocher","year":"2024","unstructured":"Bocher O, Singh A, Huang Y, V\u00f5sa U, Reimann E, Arruda A, et al. Disentangling the consequences of type 2 diabetes on targeted metabolite profiles using causal inference and interaction QTL analyses. PLOS Genet Public Libr Sci. 2024;20:e1011346. https:\/\/doi.org\/10.1371\/journal.pgen.1011346.","journal-title":"PLOS Genet Public Libr Sci"},{"key":"3083_CR24","doi-asserted-by":"publisher","first-page":"e001847","DOI":"10.1136\/bmjdrc-2020-001847","volume":"9","author":"J An","year":"2021","unstructured":"An J, Nichols GA, Qian L, Munis MA, Harrison TN, Li Z, et al. Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes. BMJ Open Diabetes Res Care. 2021;9:e001847. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001847.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3083_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/dme.12353","volume":"31","author":"TME Davis","year":"2014","unstructured":"Davis TME, Coleman RL, Holman RR, UKPDS Group. Ethnicity and long-term vascular outcomes in type 2 diabetes: a prospective observational study (UKPDS 83). Diabet Med J Br Diabet Assoc. 2014;31:200\u20137. https:\/\/doi.org\/10.1111\/dme.12353.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"3083_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jdiacomp.2017.09.010","volume":"32","author":"A Gedebjerg","year":"2018","unstructured":"Gedebjerg A, Almdal TP, Berencsi K, Rungby J, Nielsen JS, Witte DR, et al. Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: a cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. J Diabetes Complications. 2018;32:34\u201340. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.09.010.","journal-title":"J Diabetes Complications"},{"key":"3083_CR27","doi-asserted-by":"crossref","unstructured":"Geng T, Zhu K, Lu Q, Wan Z, Chen X, Liu L, et al. Healthy lifestyle behaviors, mediating biomarkers, and risk of microvascular complications among individuals with type 2 diabetes: A cohort study. PLoS med. Volume 20. Public Library of Science San Francisco, CA USA; 2023. p. e1004135.","DOI":"10.1371\/journal.pmed.1004135"},{"key":"3083_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12889-021-10381-z","volume":"21","author":"M Gabler","year":"2021","unstructured":"Gabler M, Geier S, Mayerhoff L, Rathmann W. Cardiovascular disease prevalence in type 2 diabetes \u2013 an analysis of a large German statutory health insurance database. BMC Public Health. 2021;21:328. https:\/\/doi.org\/10.1186\/s12889-021-10381-z.","journal-title":"BMC Public Health"},{"key":"3083_CR29","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.2337\/dci25-0079","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K. Our common goal to prevent cirrhosis in people with type 2 diabetes. Diabetes Care. 2025;48:e155. https:\/\/doi.org\/10.2337\/dci25-0079.","journal-title":"Diabetes Care"},{"key":"3083_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41591-022-01790-7","volume":"28","author":"ATN Nair","year":"2022","unstructured":"Nair ATN, Wesolowska-Andersen A, Brorsson C, Rajendrakumar AL, Hapca S, Gan S, et al. Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nat Med Nat Publishing Group. 2022;28:982\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01790-7.","journal-title":"Nat Med Nat Publishing Group"},{"key":"3083_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa2203769","volume":"388","author":"H Pottel","year":"2023","unstructured":"Pottel H, Bj\u00f6rk J, Rule AD, Ebert N, Eriksen BO, Dubourg L, et al. Cystatin C\u2013Based equation to estimate GFR without the inclusion of race and sex. N Engl J Med Mass Med Soc. 2023;388:333\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2203769.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"3083_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7326\/M20-4366","volume":"174","author":"H Pottel","year":"2021","unstructured":"Pottel H, Bj\u00f6rk J, Courbebaisse M, Couzi L, Ebert N, Eriksen BO, et al. Development and validation of a modified full age spectrum Creatinine-Based equation to estimate glomerular filtration rate. Ann Intern Med Am Coll Physicians. 2021;174:183\u201391. https:\/\/doi.org\/10.7326\/M20-4366.","journal-title":"Ann Intern Med Am Coll Physicians"},{"key":"3083_CR33","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Calster BV, et al. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. Br Med J Publishing Group. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378.","journal-title":"Br Med J Publishing Group"},{"key":"3083_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03.","journal-title":"J Stat Softw"},{"key":"3083_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12859-018-2344-6","volume":"19","author":"S Klau","year":"2018","unstructured":"Klau S, Jurinovic V, Hornung R, Herold T, Boulesteix A-L. Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data. BMC Bioinformatics. 2018;19:322. https:\/\/doi.org\/10.1186\/s12859-018-2344-6.","journal-title":"BMC Bioinformatics"},{"key":"3083_CR36","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1002\/sim.6246","volume":"33","author":"R De Bin","year":"2014","unstructured":"De Bin R, Sauerbrei W, Boulesteix A-L. Investigating the prediction ability of survival models based on both clinical and omics data: two case studies. Stat Med. 2014;33:5310\u201329. https:\/\/doi.org\/10.1002\/sim.6246.","journal-title":"Stat Med"},{"key":"3083_CR37","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1093\/bioinformatics\/btaa046","volume":"36","author":"S Parvandeh","year":"2020","unstructured":"Parvandeh S, Yeh H-W, Paulus MP, McKinney BA. Consensus features nested cross-validation. Bioinf Oxf Acad. 2020;36:3093\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa046.","journal-title":"Bioinf Oxf Acad"},{"key":"3083_CR38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/sim.7992","volume":"38","author":"RD Riley","year":"2019","unstructured":"Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE Jr, Moons KG, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019;38:1276\u201396. https:\/\/doi.org\/10.1002\/sim.7992.","journal-title":"Stat Med"},{"key":"3083_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/aje\/kwu140","volume":"180","author":"GCS Smith","year":"2014","unstructured":"Smith GCS, Seaman SR, Wood AM, Royston P, White IR. Correcting for optimistic prediction in small data sets. Am J Epidemiol. 2014;180:318\u201324. https:\/\/doi.org\/10.1093\/aje\/kwu140.","journal-title":"Am J Epidemiol"},{"key":"3083_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jclinepi.2015.04.005","volume":"69","author":"EW Steyerberg","year":"2016","unstructured":"Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol. 2016;69:245\u20137. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.04.005.","journal-title":"J Clin Epidemiol"},{"key":"3083_CR41","doi-asserted-by":"publisher","first-page":"110234","DOI":"10.1016\/j.knosys.2022.110234","volume":"262","author":"M Krzyzi\u0144ski","year":"2023","unstructured":"Krzyzi\u0144ski M, Spytek M, Baniecki H, Biecek P. SurvSHAP(t): Time-dependent explanations of machine learning survival models. Knowl-Based Syst. 2023;262:110234. https:\/\/doi.org\/10.1016\/j.knosys.2022.110234.","journal-title":"Knowl-Based Syst"},{"key":"3083_CR42","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/sim.9275","volume":"41","author":"RD Riley","year":"2022","unstructured":"Riley RD, Collins GS, Ensor J, Archer L, Booth S, Mozumder SI, et al. Minimum sample size calculations for external validation of a clinical prediction model with a time-to-event outcome. Stat Med. 2022;41:1280\u201395. https:\/\/doi.org\/10.1002\/sim.9275.","journal-title":"Stat Med"},{"key":"3083_CR43","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1002\/sim.9025","volume":"40","author":"RD Riley","year":"2021","unstructured":"Riley RD, Debray TPA, Collins GS, Archer L, Ensor J, van Smeden M, et al. Minimum sample size for external validation of a clinical prediction model with a binary outcome. Stat Med. 2021;40:4230\u201351. https:\/\/doi.org\/10.1002\/sim.9025.","journal-title":"Stat Med"},{"key":"3083_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK biobank resource with deep phenotyping and genomic data. Nat Nat Publishing Group. 2018;562:203\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0579-z.","journal-title":"Nat Nat Publishing Group"},{"key":"3083_CR45","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.21105\/joss.01903","volume":"4","author":"M Lang","year":"2019","unstructured":"Lang M, Binder M, Richter J, Schratz P, Pfisterer F, Coors S, et al. mlr3: A modern object-oriented machine learning framework in R. J Open Source Softw. 2019;4:1903. https:\/\/doi.org\/10.21105\/joss.01903.","journal-title":"J Open Source Softw"},{"key":"3083_CR46","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1093\/bioinformatics\/btab039","volume":"37","author":"R Sonabend","year":"2021","unstructured":"Sonabend R, Kir\u00e1ly FJ, Bender A, Bischl B, Lang M. mlr3proba: an R package for machine learning in survival analysis. Bioinformatics. 2021;37:2789\u201391. https:\/\/doi.org\/10.1093\/bioinformatics\/btab039.","journal-title":"Bioinformatics"},{"key":"3083_CR47","doi-asserted-by":"publisher","first-page":"D1415","DOI":"10.1093\/nar\/gkae1056","volume":"53","author":"H Jackson","year":"2025","unstructured":"Jackson H, Oler E, Torres-Calzada C, Kruger R, Hira AS, L\u00f3pez-Hern\u00e1ndez Y, et al. MarkerDB 2.0: a comprehensive molecular biomarker database for 2025. Nucleic Acids Res. 2025;53:D1415\u201326. https:\/\/doi.org\/10.1093\/nar\/gkae1056.","journal-title":"Nucleic Acids Res"},{"key":"3083_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijcard.2019.02.030","volume":"291","author":"A Avogaro","year":"2019","unstructured":"Avogaro A, Fadini GP. Microvascular complications in diabetes: A growing concern for cardiologists. Int J Cardiol. 2019;291:29\u201335. https:\/\/doi.org\/10.1016\/j.ijcard.2019.02.030.","journal-title":"Int J Cardiol"},{"key":"3083_CR49","doi-asserted-by":"publisher","first-page":"dev146621","DOI":"10.1242\/dev.146621","volume":"147","author":"M Jakab","year":"2020","unstructured":"Jakab M, Augustin HG. Understanding angiodiversity: insights from single cell biology. Dev Camb Engl. 2020;147:dev146621. https:\/\/doi.org\/10.1242\/dev.146621.","journal-title":"Dev Camb Engl"},{"key":"3083_CR50","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/jcm11040968","volume":"11","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-Alcoholic fatty liver disease and risk of Macro- and microvascular complications in patients with type 2 diabetes. J Clin Med. 2022;11:968. https:\/\/doi.org\/10.3390\/jcm11040968.","journal-title":"J Clin Med"},{"key":"3083_CR51","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4103\/2230-8210.183480","volume":"20","author":"A Chawla","year":"2016","unstructured":"Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab. 2016;20:546\u201351. https:\/\/doi.org\/10.4103\/2230-8210.183480.","journal-title":"Indian J Endocrinol Metab"},{"key":"3083_CR52","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European society of cardiology (ESC). Eur Heart J. 2023;44:4043\u2013140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192.","journal-title":"Eur Heart J"},{"key":"3083_CR53","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1007\/s00125-002-0863-0","volume":"45","author":"A Liebl","year":"2002","unstructured":"Liebl A, Mata M, Eschw\u00e8ge E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia. 2002;45:S23\u20138. https:\/\/doi.org\/10.1007\/s00125-002-0863-0.","journal-title":"Diabetologia"},{"key":"3083_CR54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.nurpra.2016.08.012","volume":"12","author":"KA Pickett","year":"2016","unstructured":"Pickett KA. Microvascular complications of diabetes: what\u2019s relevant for practice? J Nurse Pract. 2016;12:683\u20139. https:\/\/doi.org\/10.1016\/j.nurpra.2016.08.012.","journal-title":"J Nurse Pract"},{"key":"3083_CR55","doi-asserted-by":"publisher","first-page":"100786","DOI":"10.1016\/j.mcpro.2024.100786","volume":"23","author":"BB Sun","year":"2024","unstructured":"Sun BB, Suhre K, Gibson BW. Promises and challenges of populational proteomics in health and disease. Mol Cell Proteom MCP. 2024;23:100786. https:\/\/doi.org\/10.1016\/j.mcpro.2024.100786.","journal-title":"Mol Cell Proteom MCP"},{"key":"3083_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/dme.12647","volume":"32","author":"ML Alva","year":"2015","unstructured":"Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32:459\u201366. https:\/\/doi.org\/10.1111\/dme.12647.","journal-title":"Diabet Med"},{"key":"3083_CR57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","volume":"51","author":"AR Martin","year":"2019","unstructured":"Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51:584\u201391. . https:\/\/doi.org\/10.1038\/s41588-019-0379-x","journal-title":"Nat Genet"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03083-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03083-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03083-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:49:58Z","timestamp":1781628598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03083-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3083"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03083-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the UK Biobank under application number 10205. This research adhered to the Declaration of Helsinki. Before participation, all individuals provided written consent, and approval was obtained from the North West Multi-Center Research Ethics Committee (11\/NW\/0382;\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}